A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

Exclusion Criteria

• •1. Use of systemic glucocorticoids within 3 months prior to the screening;
• •2. Use of weight loss drugs within 3 months prior to the screening.
• •3. Treatment with insulin within 1 year prior to screening (except for short-term or treatment for gestational diabetes);
• •4. Laboratory findings at the screening visit:
• •* Amylase and/or lipase \>3 x upper limit of normal (ULN);
• •* alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 x ULN;
• •* Moderate (3b) or severe renal failure or renal insufficiency or according to local contraindications for metformin;
• •* Urinary albumin creatinine ratio (UACR) ≥300 mg/g;
• •* Total bilirubin \>2.0 x ULN;
• •* Calcitonin ≥50 ng/L;
• •5. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)；
• •6. Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 6 months prior to screening and/or planned coronary, carotid or peripheral artery revascularization procedures;
• •7. Severe uncontrolled treated or untreated hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
• •8. Proliferative retinopathy, maculopathy, painful diabetic neuropathy, diabetic foot ulcer or intermittent claudication requiring acute treatment;
• •9. History of pancreatitis (acute or chronic);
• •10. Pregnancy, breast-feeding, intention of becoming pregnant during the trial; or women of childbearing potential (WOCBP) or male subject not using adequate contraceptive measures；